BioSig’s PURE EP™ System to be Featured During EPLive 2022
May 25 2022 - 8:47AM
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company advancing
electrophysiology workflow by delivering greater intracardiac
signal fidelity through its proprietary signal processing platform,
today announced that its flagship technology will be featured
during EPlive, a hybrid event taking place at St. David’s Medical
Center in Austin, Texas from June 2-3, 2022.
EPLive is a two-day intensive educational meeting for practicing
clinical cardiac electrophysiologists, electrophysiologist fellows
and general cardiologists who have an interest in treating complex
cardiac arrhythmias. During the event, BioSig will be exhibiting
and offering technology demonstrations, including features of its
newly released PURE EP NOVA-5 Software. Enhanced with NOVA-5
Software, the Company believes that the PURE EP(TM) System delivers
a new standard in signal processing, offering greater customization
and smarter workflows. Additionally, the Company will showcase the
next generation of PURE EP(TM) Software Modules currently in
advanced development stages.
The concept for EPLive was first created and developed by Dr.
Andrea Natale, Cardiac Electrophysiologist at St. David’s Medical
Center in Austin, Texas. As an internationally respected physician
and leader in the field of cardiac electrophysiology, Dr. Natale is
passionate about education, training and knowledge sharing when it
comes to delivering the best possible care to arrhythmia patients.
As the first center to commercially adopt the PURE EP(TM) System,
Dr. Natale and the physicians at Texas Cardiac Arrhythmia Institute
(TCAI) have performed over 500 cases with the PURE EP(TM)
System since its installation in November 2019.
“We have spent approximately thirteen years working in
collaboration with the physicians at TCAI to bring this important
innovation to market. Our collaboration with this center of
excellence has supported our company in so many positive ways and
we are excited to participate in this great event,” commented
Kenneth L. Londoner, Chairman and CEO of BioSig Technologies,
Inc.
To register to attend the event, please
click here.
The PURE EP(TM) is an FDA 510(k) cleared non-invasive class II
device that aims to drive procedural efficiency and efficacy in
cardiac electrophysiology. To date, more than 73
physicians have completed over 2,200 patient cases
with the PURE EP(TM) System.
Clinical data acquired by the PURE EP™ System in a multi-center
study at centers of excellence including Texas Cardiac Arrhythmia
Institute at St. David’s Medical Center and Mayo Clinic was
recently published in the Journal of Cardiovascular
Electrophysiology and is available electronically with open access
via the Wiley Online Library. Study results showed 93%
consensus across the blinded reviewers with a 75% overall
improvement in intracardiac signal quality and confidence in
interpreting PURE EP™ signals over conventional sources.
About EPLiveEPLive is an intensive, two-day
educational meeting for practicing clinical cardiac
electrophysiologists, electrophysiologist fellows and general
cardiologists who have an interest in treating complex cardiac
arrhythmias, a condition in which the heart beats with an irregular
or abnormal rhythm. Live cases broadcast from the new,
state-of-the-art Electrophysiology Center at St. David's Medical
Center, with expert commentary, will serve as the primary teaching
tool. EPLive consists of four sections: Atrial Fibrillation (A Fib)
ablation, Ventricular Tachycardia (VT) ablation, Devices, and New
Technology. The sessions consist of a combination of live and
recorded cases from TCAI and some of the world's premier centers.
Cases include procedures such as A Fib ablation and ablation of
post-A Fib atrial arrhythmias, VT ablation (endocardial and
epicardial), balloon cases (cryo, Apama and laser), CRT implants,
SQ ICD and lead extraction and venoplasty. Additionally, EPLive
will feature new technology pioneered by physicians at TCAI,
including electroporation and leadless dual chamber pacing.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve
signal fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EPä System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road
Westport, CT 06880, US
aballou@biosigtech.com
203-409-5444, x119
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2024 to May 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From May 2023 to May 2024